Ensilitech raises £4.5M seed round to deliver biologicals without refrigeration
Bristol, 28th August 2025: EnsiliTech, an award-winning biotechnology startup, has today announced the raise of its second oversubscribed funding round, securing £4.5M in seed funding to improve the way life-saving medicines are stored and transported globally. The round was led by Eos Advisory and followed on by Calculus Capital with participation from Empirical Ventures, Fink Family Office, QantX, Angel Investors Bristol (AIB), HERmesa, Penn Park Capital, chANGELS, and other individual angel investors. The funding will accelerate proof-of-concept uptake for existing and novel biopharmaceuticals by increasing throughput with new hires and enhanced infrastructure capabilities.
Led by Dr Asel Sartbaeva, the company is redefining how vaccines, antibodies, and other biologics are stored and transported. The biopharmaceutical industry relies on a 50-year-old global ‘cold chain’ system costing over $35bn annually and remaining a major barrier to access, particularly in emerging markets. EnsiliTech’s technology removes this dependency by forming a reversible silica “shell” around biologics, eliminating the need for refrigeration or freeze-drying and enabling more reliable, sustainable distribution worldwide.
EnsiliTech has already secured multiple paid Proofs of Concept and is engaged in a growing number of partnerships with global pharma and animal health companies. Alongside this commercial traction, recent safety data and new patent filings further strengthen their position to lead in biologics thermostabilisation.
“Our mission is to ensure that life-saving medicines and vaccines reach everyone, everywhere, regardless of infrastructure or geography. By eliminating the need for refrigeration, our technology significantly reduces supply-chain costs and drug waste, while also lowering the environmental impact of pharmaceutical distribution.” commented Dr Asel Sartbaeva, CEO & cofounder of Ensilitech. “This investment is a major step forward for the team, and we’re thrilled to have the backing of partners who share our vision for a more equitable and sustainable future in global healthcare.”
Anne Muir, Director of Portfolio at Eos, said: "EnsiliTech has the technology to transform how vaccines and other therapeutics are transported and stored. Reducing wastage, reducing cost and vastly improving health outcomes across the globe, this kind of science and this scale of potential sits at the core of our investment thesis at Eos.”
Johnathan Matlock, Co-Founder at Empirical Ventures, said: "EnsiliTech exemplifies our evidence-based approach: it has progressed from academic publication to licensing negotiations within three years, while systematically de-risking technical, regulatory, and commercial challenges. We believe EnsiliTech has the potential to become the category leader in biologics thermostabilisation, unlocking new global markets for vaccines, mRNA therapies, and antibodies. Our conviction is grounded in data: demonstrated technical efficacy, early in vivo safety validation, and live commercial negotiations with billion-euro pharma partners. This is an investment where we see the opportunity for both strong financial returns and significant global health impact."
We believe EnsiliTech is on track to become a category leader in next-generation biologics delivery, with the potential to improve global health outcomes while building a defensible and scalable business in a rapidly expanding market.
Congratulations to the entire EnsiliTech team on this milestone, we’re proud to continue supporting your journey and excited to see what comes next.
